Looks like San Diego life sciences and tech investment firm Avalon Ventures is in the midst of compiling its eleventh fund, looking to raise $300 million.
Fund XI, according to an SEC filing, has raised $103.5 million of the proposed $300 million from 26 investors.
This new fund is more ambitious than Avalon’s previous attempts at raising capital: The company’s tenth fund, closed in 2012, was worth up to $250 million, though it looks like it closed out at $201 million.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The biotech investment landscape has changed, of course, since 2012. On top of that, Avalon has made some bold investment choices in the past few years – highlighted in part by its partnership with GlaxoSmithKline, launched in 2013, that will fund 10 new life sciences startups. Notably, one of its portfolio companies, AnaptysBio, filed for an $86 million IPO just last week.
Outreach to Avalon Ventures to discuss the firm’s forthcoming investment plans has yet to be returned.